[Broker Focus] Guolian Securities maintains Giazi Biotech (02367) “buy” rating, indicating that its high growth rate in 2024 is expected to continue
Jinwu Financial News | According to Guolian Securities Research Report, Juzi Biotech (02367) released its 2023 annual report: 2023 revenue of 3,524 billion yuan (+49.0% YoY), net profit to mother of 1,452 billion yuan (+44.9% YoY), and adjusted net profit of 1,469 billion yuan (YoY +39.0%). According to the bank, benefiting from the refined operation of multiple online platforms and the rapid release of Kefumei Collagen Stick Essence, online direct sales revenue increased 77.5% year-on-year in 2023/revenue share increased to 61.2%. Clekin will be in the channel adjustment period and product development period in 2023. Revenue
With Giant Biogene Holding Co., Ltd. (HKG:2367) It Looks Like You'll Get What You Pay For
When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") below 9x, you may consider Giant Biogene Holding Co., Ltd. (HKG:2367) as a stock to avoid entirely with its 29.
Changes in Hong Kong stocks | Giant Biotech (02367) rose more than 5%, technological progress drives industry growth, institutions believe there is plenty of room for growth in the recombinant collagen industry
Giant Biotech (02367) rose by more than 5%. As of press time, it rose 5.51% to HK$45.95, with a turnover of HK$76.93 million.
[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare
The sales expense ratio is as high as 33% How can Giazi Biotech get rid of dependence on large single products
In March, Juzi Biotech (02367.HK), the “first recombinant collagen stock”, released financial reports.
Giant Biogene Holding (HKG:2367) Will Want To Turn Around Its Return Trends
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongsi
[Broker Focus] Dongfang Wealth Securities maintains Juzi Biotech's (02367) “gain” rating, indicating that its channel brand is expected to contribute to increased performance after adjustment
Jinwu Financial News | According to Dongfang Wealth Securities Research, Giant Biotech (02367) achieved revenue of 3,524 billion yuan (+49%) in 2023; net profit to mother of 1,452 billion yuan (+44.9%); and adjusted net profit (excluding share payments) of 1,469 billion yuan (+39%). The final dividend of 2023 is 0.44 yuan/share, and the special dividend is 0.45 yuan/share, with a total dividend rate of 61%. According to the bank, in 2023, the company can recover 2,788 billion yuan (+73%) of revenue, accounting for about 80% of revenue, and continue to expand categories such as essences, lotions, and masks. Of these, 23 years old
Gelonghui Fund Daily Report | 10 billion fund manager's big move!
Focus on the latest fund information
Shen Wan Hongyuan: The beauty market has entered a stage of steady development and is optimistic about the market space and performance transformation of key domestic brands
China's beauty market has left a decade of rapid growth and has entered a stage of steady development.
[Broker Focus] Debon Securities maintains Giant Biotech's (02367) “buy” rating, indicating that it plans to deepen its leading position in collagen in the future
Jinwu Financial News | According to Debon Securities Research Report, Giant Biotech (02367) achieved operating income of 3,524 billion/ +49.0% in '23, and net profit of 1,452 million/ +44.9%. Revenue and profit exceeded expectations, mainly due to e-commerce channel volume growth. Revenue restructuring affected overall gross margin and net margin performance. According to the split data: (1) Gross profit margin: 83.6% /-0.76pcts in '23, stable at a high level, due to a slight decline in product structure and channel structure; 23H1/23H2 was 84.1%/83.2% respectively, and profitability improved in the second half of the year
[Broker Focus] Caitong Securities maintains Giant Biotech's (02367) “gain” rating, indicating that the medical and aesthetic pipeline is expected to land within the year and open the second curve
Jinwu Financial News | According to the Caitong Securities Research Report, Gizi Biotech (02367) announced its 23-year results. In '23, we achieved revenue of 3.52 billion yuan, up 49% year on year; realized net profit of 1.45 billion yuan, up 45% year on year; realized adjusted net profit of 1.47 billion yuan, up 39% year on year. According to this bank, on the product side: 1) Kefu Mei: The position of dressing is stable, and collagen sticks maintain a high growth rate. During the 2023 618/Double 11 promotion period, the GMV of collagen sticks increased by more than 700%/200% year-on-year, and in 2023, they also launched a new series of collagen milk, collagen comfort patches, and order series, new products
GIANT BIOGENE To Go Ex-Dividend On June 17th, 2024 With 0.48472 HKD Dividend Per Share And 0.49574 HKD Special Dividend Per Share
March 26th - $GIANT BIOGENE(02367.HK)$ is trading ex-dividend on June 17th, 2024. Shareholders of record on June 18th, 2024 will receive 0.48472 HKD dividend per share and 0.49574 HKD special divi
Giant Biotech's net profit increased by 44.9% in '23, but there are still two problems in the medium to long term | Insight Research
Looking at cosmetics in the short term and relying on medical beauty for the long term?
Giant Biotech (02367.HK) net profit of 1,452 billion yuan in 2023 increased 44.9% year-on-year
Gelonghui, March 25, 丨 Giant Biotech (02367.HK) announced that for the year ended December 31, 2023, the company's total revenue was RMB 3,524 billion, an increase of 49.0% over the previous year. The main reason for the increase was that during the reporting period, the company continued to expand product types, deeply cultivate online channels, create star products, and strengthen marketing, which further enhanced the influence of products and brands, and achieved relatively rapid growth in sales revenue. Profit attributable to owners of the parent company was RMB 1,452 million, up 44.9% year on year; basic profit per share was RMB 1.49, compared to the year ended 31 December 2022
Giant Biotech (02367) will pay a final dividend of 0.44 yuan per share on July 5
Giant Biotech (02367) announced that the company will pay a final dividend of RMB per share on July 5, 2024...
GIANT BIOGENE: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Open Source Securities: Social consumption recovered steadily in January-February, focusing on gold jewelry and domestic beauty
Four main lines of investment
Giant Biogene Holding Co., Ltd.'s (HKG:2367) Stock Is Going Strong: Is the Market Following Fundamentals?
Most readers would already be aware that Giant Biogene Holding's (HKG:2367) stock increased significantly by 30% over the past three months. Given that the market rewards strong financials in the lo
[Broker Focus] Minsheng Securities maintains Juzi Biotech (02367) “Recommended” rating, indicating that the company's medical and aesthetic product pipeline can be expected in the future
Jinwu Financial News | Minsheng Securities Research Report said that on March 13, '24, Giant Biotech (02367) disclosed research progress on the recombinant collagen tri-helix structure, achieving a technical breakthrough in CHO cells to efficiently express high-temperature, compact three-helix recombinant human collagen. At the same time, the Kalijin brand launched a new recombinant collagen containing active, firming, and anti-wrinkle essence cream. According to the bank, the company relies on deep R&D strength to continue to build a multi-brand matrix. The matrix of effective skincare products continues to be rich, and the future of the medical and aesthetic product pipeline can be expected; through continuous investment in R&D technology, first-mover advantage and refined operation, it has successfully created a large single product
Changes in Hong Kong stocks | Giant Biotech (02367) can rise more than 4%, and can recover the US and Kilijin 38 to boost the volume of high-rise star products and continue to sell
The Zhitong Finance App learned that Giant Biotech (02367) rose by more than 4%. As of press release, it had risen 4.35% to HK$41.95, with a turnover of HK$806.683 million. Guotai Junan released a research report saying that Juzi Biotech's Kefu Mei and Kelijin 38 promoted high growth. The star product, Collagen Stick, maintained a strong trend, and the Klein Daemak King Mask was bright, and they are optimistic that performance will continue to rise high under the dividends of the recombinant collagen racetrack. Juzi Biocard has grown rapidly and restructured the collagen circuit. The cosmetics business continues to expand its product line, and subsequent medical and aesthetic products are expected to be relayed. CMB International pointed out that while maintaining Giant Biotech's “buy” rating, the target price
No Data